FDA Clearance Tracker · P140026-S010
Enroute Transcarotid Stent System
Last checked: Nov 20, 2026Latest source record: Aug 16, 2018 (this decision)Source: openFDAMethods & limitations
Decided
Aug 16, 2018
Approved
Time to decision
115 days
Received Apr 23, 2018. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P140026-S010
- Device name
- Enroute Transcarotid Stent System
- Applicant
- Boston Scientific Corporation
- Applicant location
- Marborough, MA
- Received
- Apr 23, 2018
- Decided
- Aug 16, 2018
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Location Change - Manufacturer/Sterilizer/Packager/Supplier
- Original approval
- P140026
Device type
- Device type
- Stent, carotid (NIM)
- Device class
- Class III
FDA's approval statement
As written in FDA's record.
Approval for label printing and final packaging at a manufacturing site located at 1213 Innsbruck Drive, Sunnyvale, California.
Source documents
Other decisions for Boston Scientific Corporation
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- SpaceOAR Flex System510(k)
K262151 · Decided Sep 11, 2026 · 78 days after receipt
Device type: Hydrogel Spacer (OVB) · Radiology & Imaging
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.